Research programme: estrogen-related receptor alpha agonists - Wyeth

Drug Profile

Research programme: estrogen-related receptor alpha agonists - Wyeth

Alternative Names: ERRα programme - Wyeth; Metabolic disorders therapeutics - Wyeth

Latest Information Update: 19 Sep 2011

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class
  • Mechanism of Action ERRalpha estrogen-related receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 19 Sep 2011 No development reported for Type-2 diabetes mellitus in USA (unspecified route)
  • 19 Sep 2011 No development reported for Metabolic syndrome in USA (unspecified route)
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top